Clone DH8.3 of EGF R/ErbB1 antibody is specific for Truncated EGFR which is also called EGFR type III, EGFRvIII or delta-EGFR (characterised by a deletion of 267 amino acids in the extracellular domain, leading to a receptor which is unable to bind ligand yet is constitutively active). Because of its impaired internalisation and degradation, EGFRvIII is known to enhance tumourigenesis. NOTE: Clone DH8.3 DOES NOT cross-react with full length or wildtype EGFR (wtEGFR).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG₁

Description

Anti-EGFRvIII antibody clone (DH8.3) recognizes EGFRvIII, a mutated form of EGFR with a truncated extracellular domain found on human tumors. Stabley trans

Scientific Data Images for EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free

Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free [NBP2-50599]

Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] - An intracellular stain was performed on A431 cells with EGFR [DH8.3] Antibody NBP2-50599R (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to DyLight 550.

Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free [NBP2-50599]

Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] - An intracellular stain was performed on A431 cells with EGFR [DH8.3] Antibody NBP2-50599AF700 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 700.

Flow Cytometry: Mouse Monoclonal EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] -

Flow Cytometry: Mouse Monoclonal EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] - Analysis of glioblastoma cell lines using EGFR Antibody. Image from a verified customer review.

Applications for EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free

Application

Recommended Usage

ELISA

1:100 - 1:2000

Flow Cytometry

1:10 - 1:1000

Immunohistochemistry

1:10 - 1:500

Immunoprecipitation

1:10 - 1:500

Western Blot

1:100 - 1:2000

Application Notes

This antibody is Cytof ready.

Reviewed Applications

Read 1 review rated 5 using NBP2-50599 in the following applications:

Flow Cytometry (1 Review)

Formulation, Preparation, and Storage

Purification

Protein G purified

Formulation

PBS

Format

BSA Free

Preservative

0.02% Sodium Azide

Concentration

1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.

Background: EGFR

Epidermal growth factor receptor (EGFR), also known as ErbB1 and HER1, is a type I glycoprotein that belongs the ErbB subfamily of receptor tyrosine kinases (RTKs), which includes ErbB2/HER2, ErbB3/HER3, and ErbB4/HER4 (1,2). EGFR plays an important role in epithelial cell development and homeostasis and as a driver of tumorigenesis in cancer (1,2). The human EGFR is protein 1210 amino acids (aa) in length with a theoretical molecular weight (MW) of 134 kDa (1). The protein consists of a short signal peptide, an extracellular domain (ECD) divided into four subdomains (I-IV), a transmembrane region, an intracellular juxtamembrane segment, a tyrosine kinase domain, and C-terminal tail (1-3). Within the ECD, human EGFR has 88-90% aa sequence identity with mouse and rat EGFR. EGFR has four known specific ligands: EGF, amphiregulin, epigen, and transforming growth factor alpha (TGF-alpha). EGFR ligands betacellulin, epiregulin, and herapin binding (HB)-EGF have dual specificity with ErbB4 (1,3). Ligand binding to the extracellular domain of EFGR leads to receptor homodimerization, or heterodimerization with other ErbB family members, and EGFR activation. This results in subsequent phosphorylation and activation of intracellular signaling pathways, such as MAPK and PI3K/Akt (2,3). EGFR signaling is essential for many cellular processes including proliferation, differentiation, migration, and apoptosis (1,3,5).

In addition to its role in normal development, EGFR mutations or overexpression is observed in many tumors, including breast cancer, non-small cell lung carcinoma (NSCLC), colon cancer, and more (3-6). Small molecule tyrosine kinase inhibitors (TKIs), like gefitinib, erlotinib, and afatinib, have shown great efficacy in treating patients with EGFR activating mutations, especially for NSCLC (4-6). However, most patients eventually develop acquired resistance to TKIs and thus combination and alternative therapies are in development (4-6). A third-generation TKI, osimertinib, is approved for NSCLC patients with resistance to first-line EGFR TKI treatment (6). Additionally, combination therapies of EGFR TKIs with monoclonal antibody immunotherapies, like anti-PD-L1, are being further investigated in clinical trials (6).

References

1. Roskoski R Jr. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers. Pharmacol Res. 2019; 139:395-411. https://doi.org/10.1016/j.phrs.2018.11.014

2. Sigismund S, Avanzato D, Lanzetti L. Emerging functions of the EGFR in cancer. Mol Oncol. 2018; 12(1):3-20. https://doi.org/10.1002/1878-0261.12155

3. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366(1):2-16. https://doi.org/10.1016/j.gene.2005.10.018

4. Liu Q, Yu S, Zhao W, Qin S, Chu Q, Wu K. EGFR-TKIs resistance via EGFR-independent signaling pathways. Mol Cancer. 2018; 17(1):53. https://doi.org/10.1186/s12943-018-0793-1

5. Harrison PT, Vyse S, Huang PH. Rare epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer. Semin Cancer Biol. 2020; 61:167-179. https://doi.org/10.1016/j.semcancer.2019.09.015

6. Wu SG, Shih JY. Management of acquired resistance to EGFR TKI-targeted therapy in advanced non-small cell lung cancer. Mol Cancer. 2018; 17(1):38. https://doi.org/10.1186/s12943-018-0777-1

Long Name

Epidermal Growth Factor Receptor

Alternate Names

EGF R, ErbB, ErbB1, HER-1, EGFR variant III

Gene Symbol

EGFR

UniProt

Q01279

Additional EGFR Products

Product Documents for EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free

Product Datasheets

Download Product Datasheets

COA

SDS

Download SDS

Product Specific Notices for EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Citations
Reviews

Related Products
Blogs

EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free

Novus Biologicals, part of Bio-Techne | Catalog # NBP2-50599

Key Product Details

Species Reactivity

Validated:

Cited:

Applications

Validated:

Cited:

Label

Antibody Source

Format

Concentration

View all EGFR Antibodies »

Product Specifications

Immunogen

Specificity

Clonality

Host

Isotype

Description

Scientific Data Images for EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free

Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free [NBP2-50599]

Flow Cytometry: EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free [NBP2-50599]

Flow Cytometry: Mouse Monoclonal EGFR Antibody (DH8.3) - EGFRvIII [NBP2-50599] -

Applications for EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free

ELISA

Flow Cytometry

Immunohistochemistry

Immunoprecipitation

Western Blot

Reviewed Applications

Formulation, Preparation, and Storage

Purification

Formulation

Format

Preservative

Concentration

Shipping

Stability & Storage

Background: EGFR

Long Name

Alternate Names

Gene Symbol

UniProt

Additional EGFR Products

Product Documents for EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free

Product Datasheets

COA

Certificate of Analysis

SDS

Product Specific Notices for EGFR Antibody (DH8.3) - EGFRvIII, Mutant - BSA Free